NWBIO.COM: Keyword Density Checker

Total words: 1022 | 2-word phrases: 254 | 3-word phrases: 284 | 4-word phrases: 300

PAGE INFO

Title	Try to keep the title under 60 characters (58 characters) Northwest Biotherapeutics Home - Northwest Biotherapeutics
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	No H1 tag on the page (0 characters)

#	Keyword	Frequency	Density
1	dcvax® – direct	7	2.46%
2	dcvax® – l	7	2.46%
3	phase iii for	4	1.41%
4	patient storiesphysician comments	3	1.06%
5	l dcvax® –	3	1.06%
6	– l dcvax®	3	1.06%
7	– l phase	3	1.06%
8	– direct dcvax®	3	1.06%
9	l phase iii	3	1.06%
10	notice of proposed	2	0.70%
11	types of inoperable	2	0.70%
12	all types of	2	0.70%
13	for all types	2	0.70%
14	of inoperable solid	2	0.70%
15	inoperable solid tumor	2	0.70%
16	iii for all	2	0.70%
17	immunotherapy patient storiesphysician	2	0.70%
18	inquiries new patient	2	0.70%
19	new patient inquiry	2	0.70%
20	slide background our	2	0.70%
21	general inquiries new	2	0.70%
22	of proposed settlement	2	0.70%
23	links contact us	2	0.70%
24	related links contact	2	0.70%
25	publications related links	2	0.70%
26	company management publications	2	0.70%
27	overview company management	2	0.70%
28	us overview company	2	0.70%
29	governance guidelines about	2	0.70%
30	home dcvax ®	2	0.70%

#	Keyword	Frequency	Density
1	– l phase iii	3	1.00%
2	dcvax® – l dcvax®	3	1.00%
3	dcvax® – l phase	3	1.00%
4	dcvax® – direct dcvax®	3	1.00%
5	– l dcvax® –	3	1.00%
6	l dcvax® – direct	3	1.00%
7	for all types of	2	0.67%
8	all types of inoperable	2	0.67%
9	types of inoperable solid	2	0.67%
10	us overview company management	2	0.67%
11	iii for all types	2	0.67%
12	of inoperable solid tumor	2	0.67%
13	phase iii for all	2	0.67%
14	notice of proposed settlement	2	0.67%
15	corporate governance guidelines about	2	0.67%
16	for gbm brain cancer	2	0.67%
17	iii for gbm brain	2	0.67%
18	phase iii for gbm	2	0.67%
19	patient storiesphysician comments product	2	0.67%
20	l phase iii for	2	0.67%
21	overview company management publications	2	0.67%
22	inquiries new patient inquiry	2	0.67%
23	immunotherapy patient storiesphysician comments	2	0.67%
24	cell immunotherapy patient storiesphysician	2	0.67%
25	dendritic cell immunotherapy patient	2	0.67%
26	candidates dcvax® – l	2	0.67%
27	home dcvax ® technology	2	0.67%
28	– direct dcvax® –	2	0.67%
29	related links contact us	2	0.67%
30	general inquiries new patient	2	0.67%
31	and growth opportunities 17	1	0.33%
32	reviews strong progress and	1	0.33%
33	northwest biotherapeutics announces positive	1	0.33%
34	biotherapeutics announces positive votes	1	0.33%
35	announces positive votes at	1	0.33%
36	17 jun 2024 northwest	1	0.33%
37	positive votes at annual	1	0.33%
38	votes at annual meeting	1	0.33%
39	biotherapeutics announces exclusive inlicense	1	0.33%
40	press releases 03 jul	1	0.33%

#	URL	Whois	Check
1	https://www.sec.gov/cgi-bin/browse-edgar?company=Northwest+Biotherapeutics&owner=exclude&action=getcompany#new_tab	Whois	sec.gov
2	https://www.facebook.com/Northwest.Biotherapeutics.NWBO	Whois	facebook.com
3	https://twitter.com/@NorthwestBio	Whois	twitter.com
4	https://www.linkedin.com/company/northwest-biotherapeutics?trk=prof-following-company-logo&goback=%2Efps_PBCK_Northwest+Biotherapeutics_1_1_1_1_1_1_2_1_Y_1_1_1_false_1_R_1_51_1_51_true_CC%2CN%2CG%2CI%2CPC%2CED%2CL%2CFG%2CTE%2CFA%2CSE%2CP%2CCS%2CF%2CDR_2_2_2_2_2_589467_2_2_2_2_2_2_2_2_2_2_2_2_2_2	Whois	linkedin.com
5	https://plus.google.com/+NWBio/posts	Whois	google.com